The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Abstract
RATIONALE: Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease have difficulty clearing pathogens from the lung and experience chronic pulmonary infections and inflammation. Death is usually a result of respiratory failure. Newly introduced therapies and aggressive management of the lung disease have resulted in great improvements in length and quality of life, with the result that the median expected survival age has reached 36 years. However, as the number of treatments expands, the medical regimen becomes increasingly burdensome in time, money, and health resources. Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety. OBJECTIVES: The Cystic Fibrosis Foundation therefore established a committee to examine the clinical evidence for each therapy and to provide guidance for the prescription of these therapies. METHODS: The committee members developed and refined a series of questions related to drug therapies used in the maintenance of pulmonary function. We addressed the questions in one of three ways, based on available evidence: (1) commissioned systematic review, (2) modified systematic review, or (3) summary of existing Cochrane reviews. CONCLUSIONS: It is hoped that the guidelines provided in this article will facilitate the appropriate application of these treatments to improve and extend the lives of all individuals with cystic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Inhaled bronchodilators for cystic fibrosis
Halfhide, C. P., Evans, H. J., & Couriel, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003428.pub2 · Cited by 66
RetractedCurrent methods of the U.S. Preventive Services Task Force
Harris, R. P., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,731
Fuchs, H. J., Borowitz, D. S., Christiansen, D. H., Morris, E. M., Nash, M. L., Ramsey, B. W., Rosenstein, B. J., Smith, A. L., & Wohl, M. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311003 · Cited by 1,539
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Self-citationEmerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Self-citationA Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043900 · Cited by 862
Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis
Konstan, M. W., Byard, P. J., Hoppel, C. L., & Davis, P. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321303 · Cited by 726
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043891 · Cited by 694
Equi, A., Balfour-Lynn, I., Bush, A., & Rosenthal, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11081-6 · Cited by 543
Konstan, M. W., Hilliard, K. A., Norvell, T. M., & Berger, M. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.2.8049828 · Cited by 520
Wolter, J. (2002) · Thorax · doi:10.1136/thorax.57.3.212 · Cited by 518
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Dorkin, H. L., Eisenberg, J. D., Gibson, R. L., Harwood, I. R., Kravitz, R. M., Schidlow, D. V., Wilmott, R. W., Astley, S. J., McBurnie, M. A., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282403 · Cited by 458
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.
Birrer, P., McElvaney, N. G., Rüdeberg, A., Sommer, C. W., Liechti-Gallati, S., Kraemer, R., Hubbard, R., & Crystal, R. G. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.1.7912987 · Cited by 382
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
McCoy, K. S., Quittner, A. L., Oermann, C. M., Gibson, R. L., Retsch-Bogart, G. Z., & Montgomery, A. B. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1804oc · Cited by 356
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
Eigen, H., Rosenstein, B. J., FitzSimmons, S., & Schidlow, D. V. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70343-8 · Cited by 344
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Jensen, T., Pedersen, S. S., Garne, S., Heilmann, C., Høiby, N., & Koch, C. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/19.6.831 · Cited by 314
ALTERNATE-DAY PREDNISONE REDUCES MORBIDITY AND IMPROVES PULMONARY FUNCTION IN CYSTIC FIBROSIS
Auerbach, H., Kirkpatrick, J., Williams, M., & Colten, H. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92929-0 · Cited by 302
Quan, J. M., Tiddens, H. A. W. M., Sy, J. P., McKenzie, S. G., Montgomery, M. D., Robinson, P. J., Wohl, M. E. B., & Konstan, M. W. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.118570 · Cited by 301
Macrolide antibiotics for cystic fibrosis
Southern, K. W., Barker, P. M., Solis-Moya, A., & Patel, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002203.pub4 · Cited by 298
Clement, A. (2006) · Thorax · doi:10.1136/thx.2005.057950 · Cited by 292
Hodson, M., Penketh, A. R. L., & Batten, J. C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90588-2 · Cited by 275
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Hodson, M. E., Gallagher, C. G., & Govan, J. R. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00248102 · Cited by 269
High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis
Tirouvanziam, R., Conrad, C. K., Bottiglieri, T., Herzenberg, L. A., Moss, R. B., & Herzenberg, L. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511304103 · Cited by 253
Nebulised hypertonic saline for cystic fibrosis
Wark, P., & McDonald, V. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001506.pub4 · Cited by 248
Ramsey, B. W., Astley, S. J., Aitken, M. L., Burke, W., Colin, A. A., Dorkin, H. L., Eisenberg, J. D., Gibson, R. L., Harwood, I. R., Schidlow, D. V., et al. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.1.145 · Cited by 231
Hubbard, R. C., McElvaney, N. G., Birrer, P., Shak, S., Robinson, W. W., Jolley, C., Wu, M., Chernick, M. S., & Crystal, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261207 · Cited by 205
Wiesemann, H. G., Steinkamp, G., Ratjen, F., Bauernfeind, A., Przyklenk, B., Döring, G., & von der Hardt, H. (1998) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199802)25:2<88::aid-ppul3>3.0.co;2-j · Cited by 200
Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis
Eng, P. A., Morton, J., Douglass, J. A., Riedler, J., Wilson, J., & Robertson, C. F. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199602)21:2<77::aid-ppul3>3.0.co;2-m · Cited by 194
Ranasinha, C., Assoufi, B., Geddes, D., Hodson, M., Empey, D., Shak, S., Christiansen, D., & Fuchs, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92297-7 · Cited by 192
Sawaya, G. F., Guirguis-Blake, J., LeFevre, M., Harris, R., Petitti, D., & for the U.S. Preventive Services Task Force (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-12-200712180-00007 · Cited by 188
Lai, H.-C., FitzSimmons, S. C., Allen, D. B., Kosorok, M. R., Rosenstein, B. J., Campbell, P. W., & Farrell, P. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421204 · Cited by 179
Pharmacokinetics of inhaled drugs
LIPWORTH, B. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00493.x · Cited by 179
Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis
Paul, K., Rietschel, E., Ballmann, M., Griese, M., Worlitzsch, D., Shute, J., Chen, C., Schink, T., Döring, G., van Koningsbruggen, S., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-959oc · Cited by 168
Stutman, H. R., Lieberman, J. M., Nussbaum, E., & Marks, M. I. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.121930 · Cited by 166
Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis
Balfour-Lynn, I. M., Lees, B., Hall, P., Phillips, G., Khan, M. A., Flather, M. D., & Elborn, J. S. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200511-1808oc · Cited by 150
Frederiksen, B., Pressler, T., Hansen, A., Koch, C., & Høiby, N. (2006) · Acta Paediatrica · doi:10.1080/08035250600752466 · Cited by 149
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah, P. L., Scott, S. F., Knight, R. A., Marriott, C., Ranasinha, C. D., & Hodson, M. E. (1996) · Thorax · doi:10.1136/thx.51.2.119 · Cited by 149
Inhaled corticosteroids for cystic fibrosis
Balfour-Lynn, I. M., & Welch, K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001915.pub5 · Cited by 148
MacLusky, I., Gold, R., Corey, M. L., & Levison, H. (1989) · Pediatric Pulmonology · doi:10.1002/ppul.1950070110 · Cited by 148
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
Smith, A. L., Ramsey, B. W., Hedges, D. L., Hack, B. D., Williams‐Warren, J., Weber, A., Gore, E. J., & Redding, G. J. (1989) · Pediatric Pulmonology · doi:10.1002/ppul.1950070413 · Cited by 147
Long‐term tobramycin aerosol therapy in cystic fibrosis
Steinkamp, G., Tümmler, B., Gappa, M., von der Hardt, H., Potel, J., Albus, A., & Döring, G. (1989) · Pediatric Pulmonology · doi:10.1002/ppul.1950060207 · Cited by 144
High-Dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial
Lands, L. C., MILNER, R. A., Cantin, A. M., Manson, D. E., & Corey, M. L. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.04.009 · Cited by 141
McCoy, K., Hamilton, S., & Johnson, C. A. (1996) · CHEST Journal · doi:10.1378/chest.110.4.889 · Cited by 141
Aitken, M. L. (1992) · JAMA · doi:10.1001/jama.267.14.1947 · Cited by 139
Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.
Weaver, L. T., Green, M. R., Nicholson, K., Mills, J. L., Heeley, M. E., Kuzemko, J. A., Austin, S., Gregory, G. A., Dux, A., & Davis, J. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.70.2.84 · Cited by 127
Murphy, T. D., Anbar, R. D., Lester, L. A., Nasr, S. Z., Nickerson, B. G., VanDevanter, D. R., & Colin, A. A. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.20097 · Cited by 121
Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4
Lawrence, R., & Sorrell, T. C. (1993) · The Lancet · doi:10.1016/0140-6736(93)91594-c · Cited by 118
Prevalence and Mechanisms of Gastro-Oesophageal Reflux in Adult Cystic Fibrosis Patients
Ledson, M. J., Tran, J., & Walshaw, M. J. (1998) · Journal of the Royal Society of Medicine · doi:10.1177/014107689809100103 · Cited by 115
van Haren, E. H. J., Lammers, J. J., Festen, J., Heijerman, H. G. M., Groot, C. A. R., & van Herwaarden, C. L. A. (1995) · Respiratory Medicine · doi:10.1016/0954-6111(95)90249-x · Cited by 112
Nebulised anti-pseudomonal antibiotics for cystic fibrosis
RYAN, G. F., Mukhopadhyay, S., & Singh, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021 · Cited by 110
Dornase alfa for cystic fibrosis
Jones, A. P., & Wallis, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001127.pub2 · Cited by 110
Tramper‐Stranders, G. A., Wolfs, T. F. W., Fleer, A., Kimpen, J. L. L., & van der Ent, C. K. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000247109.44249.ac · Cited by 110
Stead, R. J., Hodson, M. E., & Batten, J. C. (1987) · British Journal of Diseases of the Chest · doi:10.1016/0007-0971(87)90161-6 · Cited by 109
Retsch‐Bogart, G. Z., Burns, J. L., Otto, K., Liou, T. G., McCoy, K., Oermann, C. M., Gibson, R. L., & AZLI Phase II Study Group (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20736 · Cited by 107
Recombinant Human DNase Inhalation in Normal Subjects and Patients With Cystic Fibrosis
Aitken, M. L. (1992) · JAMA · doi:10.1001/jama.1992.03480140073036 · Cited by 107
Dornase Alfa Reduces Air Trapping in Children With Mild Cystic Fibrosis Lung Disease
Robinson, T. E., Goris, M. L., Zhu, H. J., Chen, X., Bhise, P., Sheikh, F., & Moss, R. B. (2005) · CHEST Journal · doi:10.1378/chest.128.4.2327 · Cited by 101
Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
Balfour-Lynn, I. M., Klein, N. J., & Dinwiddie, R. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.2.124 · Cited by 100
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Walters, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912 · Cited by 100
Nebulized gentamicin in children and adolescents with cystic fibrosis
KUN, P., Landau, L. I., & Phelan, P. D. (1984) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.1984.tb00035.x · Cited by 97
Nasr, S. Z., Kuhns, L. R., Brown, R. W., Hurwitz, M. E., Sanders, G., & Strouse, P. J. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.1061 · Cited by 95
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Rosenfeld, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912.pub4 · Cited by 91
Erythromycin and diffuse panbronchiolitis.
Koyama, H., & Geddes, D. M. (1997) · Thorax · doi:10.1136/thx.52.10.915 · Cited by 89
Shah, P. L., Bush, A., Canny, G., Colin, A., Fuchs, H. J., Geddes, D. M., Johnson, C., Light, M., Scott, S., De, T., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08060954 · Cited by 88
Чучалин, А. Г., r, E. C., Gyurkovics, K. L. N., Trawinska-Bartnicka, M., Sands, D., Kapranov, N. I., Varoli, G., Preti, P. A. M., & Mazurek, H. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709001-00004 · Cited by 86
Dornase alfa for cystic fibrosis
Jones, A. P., Wallis, C., & Kearney, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001127 · Cited by 86
Effect of rhDNase on Airflow Obstruction and Mucociliary Clearance in Cystic Fibrosis
Laube, B. L., Auci, R. M., Shields, D. E., Christiansen, D. H., Lucas, M. K., Fuchs, H. J., & Rosenstein, B. J. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.2.8564129 · Cited by 86
Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects
Konstan, M. W., Krenicky, J. E., Finney, M. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052449 · Cited by 84
Dornase Alfa as Postoperative Therapy in Cystic Fibrosis Sinonasal Disease
Cimmino, M., Nardone, M., Cavaliere, M., Plantulli, A., Sepe, A. O., Esposito, V., Mazzarella, G., & Raia, V. (2005) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.131.12.1097 · Cited by 84
Lenoir, G., Antypkin, Y. G., Miano, A., Moretti, P., Zanda, M., Varoli, G., Preti, P. A. M., & Aryayev, N. L. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709001-00003 · Cited by 82
Ordoñez, C. L., Stulbarg, M. S., Grundland, H., Liu, J. T., & Boushey, H. A. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.1085 · Cited by 81
Microbiological and Immunologic Considerations With Aerosolized Drug Delivery
LiPuma, J. J. (2001) · CHEST Journal · doi:10.1378/chest.120.3_suppl.118s · Cited by 79
Loening-Baucke, V. A., Mischler, E. H., & Myers, M. G. (1979) · The Journal of Pediatrics · doi:10.1016/s0022-3476(79)80785-4 · Cited by 78
Variability of airways hyper-reactivity and allergy in cystic fibrosis.
Holzer, F. J., Olinsky, A., & Phelan, P. D. (1981) · Archives of Disease in Childhood · doi:10.1136/adc.56.6.455 · Cited by 73
Ballmann, M., & von der Hardt, H. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(01)00009-1 · Cited by 72
Ratjen, F. A., W�nne, R., Posselt, H., St�ver, B., Hofmann, D., & Bender, S. W. (1985) · European Journal of Pediatrics · doi:10.1007/bf00441781 · Cited by 69
Wilmott, R. W., Amin, R. S., Colin, A. A., DeVault, A. R., Dozor, A. J., Eigen, H., Johnson, C. A., Lester, L., McCoy, K., McKean, L. P., et al. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.6.8665055 · Cited by 68
Shah, P. L., Scott, S. F., Geddes, D. M., & Hodson, M. E. (1995) · Respiratory Medicine · doi:10.1016/0954-6111(95)90126-4 · Cited by 67
Fitzgerald, D. A., Hilton, J., Jepson, B., & Smith, L. (2005) · PEDIATRICS · doi:10.1542/peds.2005-0308 · Cited by 67
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis
Lands, L., Dezateux, C. A., & Crighton, A. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001505 · Cited by 59
CHRONIC PSEUDOMONAS AERUGINOSA LUNG INFECTION IN CYSTIC FIBROSIS
Schiøtz, P. O., Jørgensen, M. H., Flensborg, E. W., et al. (1983) · Acta Paediatrica · doi:10.1111/j.1651-2227.1983.tb09712.x · Cited by 58
Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment.
Beardsmore, C., Thompson, J. R., Williams, A., McArdle, E. K., Gregory, G. A., Weaver, L. T., & Simpson, H. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.71.2.133 · Cited by 58
Suri, R. (2002) · Thorax · doi:10.1136/thorax.57.10.841 · Cited by 57
A Controlled Trial of Long-term Bronchodilator Therapy in Cystic Fibrosis
Eggleston, P. A., Rosenstein, B. J., Stackhouse, C. M., Mellits, E. D., & Baumgardner, R. A. (1991) · CHEST Journal · doi:10.1378/chest.99.5.1088 · Cited by 51
Stafanger, G., Garne, S., Howitz, P., et al. (1988) · European Respiratory Journal · doi:10.1183/09031936.93.01020161 · Cited by 51
RhDNase before airway clearance therapy improves airway patency in children with CF
van der Giessen, L. J., de Jongste, J. C., Gosselink, R., Hop, W. C. J., & Tiddens, H. A. W. M. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20636 · Cited by 44
Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?
Boeck, K. D., Baets, F. D., Malfroot, A., Desager, K., Mouchet, F., & Proesmans, M. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0198-9 · Cited by 41
DNase in stable cystic fibrosis infants: a pilot study
ten Berge, M., van der Wiel, E., Tiddens, H. A. W. M., Merkus, P. J. F. M., Hop, W. C. J., & de Jongste, J. C. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(03)00090-0 · Cited by 37
Oral anti-pseudomonal antibiotics for cystic fibrosis
Remmington, T., Jahnke, N., & Harkensee, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005405.pub4 · Cited by 36
Eisenberg, J. D., Aitken, M. L., Dorkin, H. L., Harwood, I. R., Ramsey, B. W., Schidlow, D. V., Wilmott, R. W., Wohl, M. E. B., Fuchs, H. J., Christiansen, D. H., et al. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70134-3 · Cited by 36
Dornase alpha and exhaled NO in cystic fibrosis
Grasemann, H., Lax, H., Treseler, J., & Colin, A. A. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.20088 · Cited by 31
Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis
Dodd, J. D., Barry, S. C., Daly, L., & Gallagher, C. G. (2005) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.11.004 · Cited by 31
Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients
Heijerman, H. G. M., van Rossem, R. N., & Bakker, W. (1995) · The Netherlands Journal of Medicine · doi:10.1016/0300-2977(95)00022-f · Cited by 26
Is primary prevention of asthma possible?
Becker, A. B. (2000) · Pediatric Pulmonology · doi:10.1002/1099-0496(200007)30:1<16::aid-ppul4>3.0.co;2-h · Cited by 25
Efficacy of Human Recombinant DNase in Pediatric Patients with Cystic Fibrosis
Furuya, M. E. Y., Lezana, J. L., Vargas, M. H., Hernández-Sierra, J. F., & Ramírez-Figueroa, J. L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00258-7 · Cited by 17
Chua, H. L., Walker, S. L., Souëf, P. N. L., et al. (1993) · Pediatric Pulmonology · doi:10.1002/ppul.1950160507 · Cited by 15
Cited by
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Airway Mucus Function and Dysfunction
Fahy, J. V., & Dickey, B. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0910061 · Cited by 1,722
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Self-citationO'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Self-citation
Metadata
- Authors
- Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., Rosenblatt, R., Vender, R. L., Hazle, L., Sabadosa, K., & Marshall, B.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-15
- Volume
- 176
- Issue
- 10
- Pages
- 957-969
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2124135806
- Cited by
- 1,024
- References
- 97
- FWCI
- 36.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.